All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
DUBLIN – In what continues to be a year like no other, European biotechnology firms engaged in drug development raised $4.783 billion in equity financing during the third quarter. It is an unprecedented level of funding for the sector.